SVB Leerink initiated coverage on shares of Legend Biotech (NASDAQ:AMTI) in a report released on Tuesday morning, BenzingaRatingsTable reports. The firm issued an outperform rating and a $32.00 target price on the stock. SVB Leerink also issued estimates for Legend Biotech’s Q2 2020 earnings at ($0.35) EPS, Q3 2020 earnings at ($0.42) EPS, Q4 2020 earnings at ($0.50) EPS, FY2020 earnings at ($1.77) EPS, FY2021 earnings at ($2.12) EPS, FY2022 earnings at ($1.91) EPS, FY2023 earnings at ($2.09) EPS and FY2024 earnings at ($2.28) EPS.
Separately, Bank of America assumed coverage on shares of Legend Biotech in a research report on Tuesday. They set a buy rating and a $34.00 price objective on the stock.
Legend Biotech stock opened at $27.00 on Tuesday. Legend Biotech has a fifty-two week low of $17.05 and a fifty-two week high of $31.84.
Applied Molecular Transport Inc develops biological therapeutics to treat autoimmune, metabolic, and inflammatory diseases.. The company develops submucosal biopharmaceuticals and bio-betters. Applied Molecular Transport Inc was incorporated in 2010 and is based in South San Francisco, California.
See Also: Equal Weight Rating
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.